Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Estrogen Receptor Positive Breast Cancer Clear all
Not yet recruiting Phase 2 Interventional

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
65
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jun 10, 2026, 8:50 PM EDT
Terminated Phase 2 Interventional Results available

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

NCT01776008
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jun 10, 2026, 8:50 PM EDT
Withdrawn Phase 2 Interventional

Fulvestrant + Neratinib In Breast Cancer

NCT04901299
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
core needle biopsy, blood draw
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting Phase 3 Interventional

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
47
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

NCT01216176
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05191004
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions
NUV-422, Fulvestrant
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jun 10, 2026, 8:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

NCT04504916
View directory record Official record
Conditions
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Zilovertamab vedotin
Drug
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial for Large ER-Negative Breast Cancers

NCT01869192
View directory record Official record
Conditions
Malignant Neoplasm of Female Breast
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

NCT02392611
View directory record Official record
Conditions
Solid Tumors and Lymphomas
Interventions
Alobresib, Exemestane, Fulvestrant
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Early Phase 1 Interventional

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

NCT02538484
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Fish Oil
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Jun 10, 2026, 8:50 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
22
States / cities
Duarte, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
54
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

NCT03774472
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Hydroxychloroquine, Letrozole, Palbociclib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis, Nab-paclitaxel, Paclitaxel, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
703
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jun 10, 2026, 8:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
View directory record Official record
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 10, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

NCT00073528
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Lapatinib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
84
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jun 10, 2026, 8:50 PM EDT